Aytu BioPharma (NASDAQ:AYTU) Given New $12.50 Price Target at Ascendiant Capital Markets

Aytu BioPharma (NASDAQ:AYTU) had its target price lifted by Ascendiant Capital Markets from $12.00 to $12.50 in a research note published on Thursday morning,Benzinga reports. Ascendiant Capital Markets currently has a buy rating on the stock.

A number of other analysts also recently issued reports on AYTU. Lake Street Capital started coverage on shares of Aytu BioPharma in a report on Tuesday, July 1st. They issued a “buy” rating and a $8.00 price objective for the company. Wall Street Zen cut shares of Aytu BioPharma from a “strong-buy” rating to a “buy” rating in a research report on Saturday, July 5th. Three investment analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $9.17.

Aytu BioPharma Stock Performance

NASDAQ AYTU opened at $1.86 on Thursday. The company has a quick ratio of 0.87, a current ratio of 1.26 and a debt-to-equity ratio of 0.57. The company has a market capitalization of $18.43 million, a P/E ratio of -0.66 and a beta of 0.22. Aytu BioPharma has a 12-month low of $0.95 and a 12-month high of $2.85. The firm has a 50-day moving average price of $2.35 and a two-hundred day moving average price of $1.86.

Aytu BioPharma (NASDAQ:AYTU) last posted its quarterly earnings data on Tuesday, September 23rd. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.24). The business had revenue of $15.14 million during the quarter, compared to the consensus estimate of $18.06 million. Aytu BioPharma had a negative net margin of 20.43% and a positive return on equity of 13.77%.

Hedge Funds Weigh In On Aytu BioPharma

Hedge funds and other institutional investors have recently made changes to their positions in the company. Stonepine Capital Management LLC increased its position in Aytu BioPharma by 13.8% during the 1st quarter. Stonepine Capital Management LLC now owns 463,721 shares of the company’s stock worth $556,000 after purchasing an additional 56,172 shares in the last quarter. Kanen Wealth Management LLC acquired a new position in Aytu BioPharma during the 2nd quarter worth approximately $1,250,000. AWM Investment Company Inc. acquired a new position in Aytu BioPharma during the 2nd quarter worth approximately $1,351,000. Finally, FNY Investment Advisers LLC acquired a new position in Aytu BioPharma during the 2nd quarter worth approximately $78,000. 33.49% of the stock is currently owned by institutional investors and hedge funds.

About Aytu BioPharma

Aytu Biopharma, Inc is a specialty pharmaceutical company, which engages in identifying, acquiring, and commercializing novel products. It operates through the Rx and Consumer Health segments. The RX segment consists of various prescription pharmaceutical products sold through third parties. The Consumer Health segment includes various consumer health products sold directly to consumers.